Dianthus Therapeutics Inc stock is traded at $85.81, with a volume of 1,679,747. It is up +3.76% in the last 24 hours and down -2.72% over the past month. Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Previous Close:
$82.70
Open:
$85.92
24h Volume:
1,679,747
Relative Volume:
1.83
Market Cap:
$4.80B
Revenue:
$1.34M
Net Income/Loss:
-$173.66M
P/E Ratio:
-
EPS:
-$4.14
Net Cash Flow:
-$130.49M
1W Performance:
+4.25%
1M Performance:
-2.72%
6M Performance:
-3.95%
1Y Performance:
+158.46%
1-Day Range:
$82.21$85.92
1-Week Range:
$80.58$86.17
52-Week Range:
$32.42$117.88
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
929-999-4055Address
7 TIMES SQUARE, NEW YORK, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS